Restart Life Sciences Corp.
NMLSF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | 0.04 | 0.22 | 0.02 |
| FCF Yield | -10.88% | -10.96% | -10.77% | -32.53% |
| EV / EBITDA | -1.11 | -2.10 | -7.14 | -2.06 |
| Quality | ||||
| ROIC | 284.63% | 148.32% | -4,454.59% | -609.54% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | -0.32 | 0.23 | 0.59 | 0.72 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -100.00% |
| Free Cash Flow Growth | 74.14% | 80.78% | 25.82% | -361.07% |
| Safety | ||||
| Net Debt / EBITDA | -0.10 | 0.01 | 0.14 | 0.08 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -11,441.19 | -29,074.90 |